1. Headline & intro
Brain–computer interfaces (BCIs) were supposed to be a sci‑fi sideshow. Instead, they’re quietly turning into a strategic technology — and China just put a serious marker on the table. Gestala, a barely two‑month‑old startup you’d never heard of last week, has raised a record early‑stage round to build non‑invasive ultrasound BCIs. This isn’t just another healthtech story. It’s about who will control the next interface after the smartphone, who owns our neural data, and whether Europe will be a standards‑setter or a spectator.
In this piece, we unpack what Gestala is building, why ultrasound matters, how this reshapes the U.S.–China tech race, and what it should trigger in European policy circles.
2. The news in brief
According to TechCrunch, Chinese startup Gestala has raised about $21.6 million (150 million RMB) barely two months after its launch, at an early valuation reportedly between $100 million and $200 million. The round was co‑led by Guosheng Capital and Dalton Venture, with several Chinese investors participating, and was significantly oversubscribed.
Gestala, founded by serial entrepreneur Phoenix Peng, is developing non‑invasive brain–computer interfaces based on ultrasound rather than implanted electrodes. It is reportedly the first ultrasound‑focused BCI company in China, and one of several globally alongside U.S. players such as OpenAI‑backed Merge Labs.
The company plans to expand its team from 15 to around 35 employees this year, build a manufacturing facility in China, and deliver a first‑generation prototype by year‑end. Gestala is initially targeting chronic pain, mental health conditions and stroke rehabilitation, while also constructing an “Ultrasound Brain Bank” — a large neural dataset to train AI models for decoding brain activity.
3. Why this matters
Gestala is interesting for three overlapping reasons: the tech, the timing, and the geopolitics.
On the tech side, ultrasound sits in a sweet spot between today’s two main BCI camps. On one side you have invasive implants like Neuralink, which promise high‑bandwidth access to the brain but require brain surgery and face long, expensive clinical pathways. On the other side are non‑invasive methods like EEG headsets, which are safe and cheap but relatively low‑resolution and easily overwhelmed by noise.
If Gestala and its peers can make ultrasound work at scale, you get something qualitatively different: non‑invasive access that is deeper and more precise than EEG, able not just to read but to stimulate or suppress activity in specific brain regions. That is a huge leap for treating chronic pain, depression or Parkinson’s — and a step toward much richer human–computer interaction.
The timing matters because capital is starting to converge on neurotech in a way we last saw around 2020–2021 for fintech and crypto. A record early‑stage round in China signals to founders and investors that BCI is no longer fringe. Expect more copycats, more labs spinning out companies, and more big‑tech interest — especially from firms already investing heavily in AI and wearables.
Geopolitically, Gestala is a reminder that neurotechnology is becoming part of the U.S.–China deep‑tech rivalry. Brain data and neuromodulation tools are not just for healthcare; they touch defense, workforce productivity, mental health at population scale — in other words, levers of power states care about. A Chinese startup claiming speed and scale advantages in clinical trials and manufacturing will not go unnoticed in Washington or Brussels.
The immediate winners are Chinese hospitals and researchers, who get access to cutting‑edge non‑invasive tools at lower cost. The losers, potentially, are Western startups that suddenly look slower and more expensive — and regulators who are still treating BCIs like a niche medical device category rather than an emerging general‑purpose technology.
4. The bigger picture
Gestala doesn’t appear in a vacuum. It plugs into several ongoing shifts in brain tech.
First, the center of gravity is moving away from pure implants. Neuralink made headlines with its first human implant, and companies like Synchron and Paradromics are pushing minimally invasive approaches. But in parallel, there’s a clear investment wave around safer, easier‑to‑deploy modalities: ultrasound, focused magnetic stimulation, advanced EEG and near‑infrared spectroscopy. The logic is simple: non‑invasive devices can be tested and shipped faster, to more people, for more use cases.
Second, BCIs are being reframed from “gadgets” to data platforms. Gestala’s “Ultrasound Brain Bank” is not a side project; it’s the business moat. Whoever builds the largest, highest‑quality, well‑labelled neural datasets will be best positioned to train AI models that decode intentions, emotions and pathological patterns. This mirrors what happened in computer vision and speech: hardware is necessary, but data and models drive defensibility.
Third, we are seeing convergence between AI and neurotech. The same transformer architectures that map text to meaning can be adapted to map noisy neural signals to actions or diagnoses, provided the data exists. Gestala’s promise to run large‑scale, low‑cost clinical studies in Chinese hospitals is precisely about feeding those models. If it succeeds, you don’t just get a better device; you get a brain‑level analytics stack.
Compared with U.S. players, Gestala is betting harder on manufacturing and clinical throughput as strategic assets. Neuralink has built custom chips and surgical robots; Merge Labs focuses on ultrasound but still operates in a U.S. regulatory and cost environment. Gestala is effectively saying: we will do similar science, but at Chinese speed and scale.
That should worry any competitor that assumes regulatory advantage in the West is enough. It also raises uncomfortable questions: will the world’s most powerful brain‑decoding models be trained mainly on Chinese patients? And what values — scientific, commercial, political — will be embedded in how those models are used?
5. The European angle
For Europe, Gestala is both a warning and an opportunity.
On the one hand, it underlines how far EU policy is lagging behind the frontier of neurotech. We have GDPR to regulate personal data, the Medical Device Regulation (MDR) to govern clinical devices, and now the EU AI Act to classify high‑risk systems. But none of these fully grapples with neural data — which is essentially the raw material of thoughts, moods and intentions.
A Chinese company building a massive “Ultrasound Brain Bank” will immediately trigger red flags under GDPR if any European data is involved: questions of purpose limitation, data minimisation, and international transfers to a jurisdiction with very different state‑access norms. It also intersects with the AI Act’s spirit: BCIs for medical use will almost certainly be treated as high‑risk, demanding strict transparency, robustness and human oversight.
On the other hand, Europe has a deep bench of neuroscience and medical‑device expertise. From Swiss neurorehab pioneers like MindMaze to German neuromodulation and imaging companies, the region knows how to bring complex hardware through regulatory pathways. Startups in Berlin, Paris, Zürich or Stockholm can absolutely compete on scientific quality.
The problem is speed and cohesion. Clinical trials in the EU are slower and more expensive than in China, and funding is more fragmented. If Europe only responds with restrictions on foreign neurotech, it will fall behind. The smarter response is twofold: actively fund European non‑invasive BCI research — including ultrasound — and move quickly to define neuro‑rights and neural‑data standards that could become global benchmarks.
For European hospitals and insurers, Gestala’s pitch of low‑cost clinical trials in China will be tempting. But outsourcing brain data collection to another jurisdiction is strategically shortsighted. The EU should ensure that trials on European patients are run under European governance, even if foreign devices are involved.
6. Looking ahead
Over the next three to five years, several fault lines will determine whether Gestala becomes a global player or mainly a domestic champion.
Clinical proof over hype. Chronic pain is a rational lead indication: large patient populations, high unmet need, and some prior academic evidence for ultrasound neuromodulation. The key questions: Can Gestala show durable, statistically significant improvements over existing treatments? And can it do so with a safety profile that makes non‑specialist clinicians comfortable?
Regulatory strategy. Moving quickly in China is one thing; obtaining approvals in the U.S. (FDA) and Europe (CE marking under MDR) is quite another. If Gestala sidelines Western regulators, it will limit itself to markets that accept Chinese approvals or are willing to run parallel trials. If it engages early, expect fierce debates around data access, algorithm transparency and post‑market surveillance.
Data governance and trust. Building an “Ultrasound Brain Bank” sounds powerful — and vaguely ominous. Patients, clinicians and regulators will ask: Who owns the data? How is it anonymised? Can it be accessed by the state? Can models trained on patient data be used for non‑medical purposes, such as attention optimisation in education or workplace monitoring?
Export controls and techno‑politics. As BCIs edge closer to dual‑use (civilian and military) technology, both the U.S. and China may start treating advanced neurotech like semiconductors or AI accelerators — subject to export controls, investment screening and security reviews. Gestala could one day find itself on the same policy battlefield as Huawei and high‑end chipmakers, albeit in a more niche corner.
For readers — whether you’re in healthcare, AI or policy — the main thing to watch is who sets the norms. If companies like Gestala, Neuralink and Merge move faster than regulators and ethicists, de facto standards will be created by the first products that scale, not by thoughtful public debate.
7. The bottom line
Gestala’s funding round is more than a big cheque for a small Chinese startup. It’s an early sign that non‑invasive, ultrasound‑based BCIs are entering the global race for the next computing interface — and that China intends to compete on speed, scale and data. Europe and the U.S. can either treat this as a wake‑up call to invest, regulate and define neuro‑rights, or watch a new layer of critical technology solidify elsewhere. The uncomfortable question is simple: who do you trust with your brain data?
